Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.

Activation of 17beta-estradiol (E2) through the formation of catechol estrogen metabolites, 2-OH-E2 and 4-OH-E2, and the C-16alpha hydroxylation product, 16alpha-OH-E2, has been postulated to be a factor in mammary carcinogenesis. Cytochrome P450 1B1 (CYP1B1) exceeds other P450 enzymes in both estrogen hydroxylation activity and expression level in breast tissue. To determine whether inherited variants of CYP1B1 differ from wild-type CYP1B1 in estrogen hydroxylase activity, we expressed recombinant wild-type and five polymorphic variants of CYP1B1: variant 1 (codon 48Arg-->Gly), variant 2 (codon 119Ala-->Ser), variant 3 (codon 432Val-->Leu), variant 4 (codon453Asn-->Ser), variant 5 (48Gly, 119Ser, 432Leu, 453Ser). The His-tagged proteins were purified by nickel-nitrilotriacetic acid (Ni-NTA) chromatography and analyzed by electrophoresis and spectrophotometry. We performed assays of E2 hydroxylation activity and quantitated production of 2-OH-E2, 4-OH-E2, and 16alpha-OH-E2 by gas chromatography/mass spectrometry. Wild-type CYP1B1 formed 4-OH-E2 as main product (Km, 40+/-8 microM; k(cat) 4.4+/-0.4, min(-1); k(cat)/Km, 110 mM(-1) min(-1)), followed by 2-OH-E2 (Km, 34+/-4 microM; k(cat), 1.9+/-0.1 min(-1); k(cat)/Km, 55 mM(-1)min(-1)) and 16alpha-OH-E2 (Km, 39+/-5.7 microM; k(cat), 0.30+/-0.02 min(-1); k(cat)/Km, 7.6 mM(-1)min(-1)). The CYP1B1 variants also formed 4-OH-E2 as the main product but displayed 2.4- to 3.4-fold higher catalytic efficiencies k(cat)/Km than the wild-type enzyme, ranging from 270 mM(-1)min(-1) for variant 4, to 370 mM(-1)min(-1) for variant 2. The variant enzymes also exceeded wild-type CYP1B1 with respect to 2- and 16alpha-hydroxylation activity. Thus, inherited alterations in CYP1B1 estrogen hydroxylation activity may be associated with significant changes in estrogen metabolism and, thereby, may possibly explain interindividual differences in breast cancer risk associated with estrogen-mediated carcinogenicity.

[1]  J. Liehr,et al.  Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. , 2000, Cancer research.

[2]  T. Shimada,et al.  Catalytic properties of polymorphic human cytochrome P450 1B1 variants. , 1999, Carcinogenesis.

[3]  N. Roodi,et al.  Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.

[4]  T. Shimada,et al.  Recombinant human cytochrome P450 1B1 expression in Escherichia coli. , 1998, Archives of biochemistry and biophysics.

[5]  A. Child,et al.  Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. , 1998, American journal of human genetics.

[6]  P. Hollenberg,et al.  Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. , 1998, Archives of biochemistry and biophysics.

[7]  J. Lupski,et al.  Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. , 1998, American journal of human genetics.

[8]  K. Patil,et al.  Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Sarfarazi,et al.  Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. , 1997, Human molecular genetics.

[10]  N. Walker,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Keyomarsi,et al.  Expression of cytochromes P450 in human breast tissue and tumors. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[12]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[13]  F P Perera,et al.  Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. , 1996, Journal of the National Cancer Institute.

[14]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Bolton,et al.  Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. , 1996, Chemical research in toxicology.

[16]  F. Guengerich,et al.  New applications of bacterial systems to problems in toxicology. , 1996, Critical reviews in toxicology.

[17]  J. Liehr,et al.  Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: correlation of DNA damage by free radicals with metabolic activation to quinones. , 1995, Carcinogenesis.

[18]  U. Meyer,et al.  Truncated human P450 2D6: expression in Escherichia coli, Ni(2+)-chelate affinity purification, and characterization of solubility and aggregation. , 1995, Archives of biochemistry and biophysics.

[19]  H. Yamazaki,et al.  Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. , 1995, Archives of biochemistry and biophysics.

[20]  H. Yamazaki,et al.  Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities , 1995 .

[21]  C. Jefcoate,et al.  The effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: Evidence for induction of a novel 17β-estradiol 4-hydroxylase , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  E. Jabs,et al.  Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. , 1994, The Journal of biological chemistry.

[23]  J. Liehr,et al.  DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. , 1994, Carcinogenesis.

[24]  G. Vollmer,et al.  Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  B. Mannervik,et al.  Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. Nutter,et al.  An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. , 1994, Chemical research in toxicology.

[27]  G. Vollmer,et al.  Catecholestrogens are MCF-7 cell estrogen receptor agonists , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  D. Nebert,et al.  Elevated estrogen 16 alpha-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk? , 1993, Journal of the National Cancer Institute.

[29]  M. Osborne,et al.  Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. , 1993, Journal of the National Cancer Institute.

[30]  E. Cavalieri,et al.  Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. , 1992, Chemical research in toxicology.

[31]  E. Schuetz,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. , 1992, Archives of biochemistry and biophysics.

[32]  T. Aoyama,et al.  Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.

[33]  K. Korzekwa,et al.  Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. , 1990, Endocrinology.

[34]  J. Liehr.  Genotoxic effects of estrogens. , 1990, Mutation research.

[35]  D. Roy,et al.  The O-methylation of 4-hydroxyestradiol is inhibited by 2-hydroxyestradiol: implications for estrogen-induced carcinogenesis. , 1990, Carcinogenesis.

[36]  J. Liehr,et al.  Free radical generation by redox cycling of estrogens. , 1990, Free radical biology & medicine.

[37]  J. Wittliff,et al.  Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. , 1989, Journal of steroid biochemistry.

[38]  P. Cisek,et al.  Catechol estrogen adducts. , 1988, Journal of steroid biochemistry.

[39]  Li Jj,et al.  Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. , 1987 .

[40]  H. Strobel,et al.  Cytochrome P-450-mediated redox cycling of estrogens. , 1986, The Journal of biological chemistry.

[41]  J. Liehr,et al.  Carcinogenicity of catechol estrogens in Syrian hamsters. , 1986, Journal of steroid biochemistry.

[42]  F. Naftolin,et al.  Kinetics of catechol estrogen-estrogen receptor dissociation: A possible factor underlying differences in catechol estrogen biological activity , 1983, Steroids.

[43]  F. Guengerich.  Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome p-450 reductase related to catalysis in reconstituted systems. , 1983, Biochemistry.

[44]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.